Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Osaka, Japan – August 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics. The list of approved products: 1. Pregabalin OD Tablets, Capsules Generic name: Pregabalin* Strengths: OD Tablets, Capsules: 25mg, 75mg, 150mg Brand products: Lyrica® OD Tablets 25mg, 75mg, 150mg, Lyrica® Capsules 25mg, 75mg, 150mg 2. Rivastigmine Tapes Generic name: Rivastigmine* Strengths: 4.5mg, 9mg, 13.5mg, 18mg Brand products: EXELON® PATCH 4.5mg, 9mg, 13.5mg, 18mg, RIVASTACH® Patches 4.5mg, 9mg, 13.5mg, 18mg 3. Bortezomib for Injection Generic name: Bortezomib Strengths: 3mg Brand products: VELCADE® Injection 3mg 4. Famotidine Intravenous Injection Generic name: Famotidine Strengths: 10mg, 20mg Brand products: Gaster® Injection 10mg, 20mg The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

The release as fetched from its publisher. upsher-smith.com ↗